Clinical trials - Press Releases

Date	Title	Company
06-Dec-2022	MHRA approves Adtralza®▼(tralokinumab) for the treatment of adolescent patients with moderate-to-severe atopic dermatitis, who are candidates for systemic therapy	LEO Pharma
06-Dec-2022	Medidata Launches New myMedidata Native App to Expedite Study Start Up and Improve Patient Experience	Medidata
06-Dec-2022	Achilles Therapeutics Presents Encouraging Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma at ESMO IO Congress 2022	Achilles Therapeutics
06-Dec-2022	Spago Nanomedical initiates clinical trial with SpagoPix in endometriosis and concludes SPAGOPIX-01	Spago Nanomedical
06-Dec-2022	Novotech Awarded the Asia Pacific CRO of the Year 2022 for Best Practices in Clinical Trials	Novotech
01-Dec-2022	The Mobile Health/Central Lab Interface, an opportunity for DCT efficiency	mdgroup
28-Nov-2022	NUBEQA®▼ (darolutamide) + ADT in combination with docetaxel licenced by MHRA and made immediately available through NHS England early access deal for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC)	Health Unlimited
24-Nov-2022	SPRAVATO®▼ (esketamine) nasal spray data from the phase 3b ESCAPE-TRD study demonstrate superior efficacy compared to quetiapine extended-release in treatment-resistant major depressive disorder1	Janssen Pharmaceutical Companies of Johnson & Johnson
23-Nov-2022	STORM Therapeutics doses first patient with oral METTL3 targeting drug candidate in a solid tumor Phase 1 study	STORM Therapeutics
23-Nov-2022	World’s first clinical trial to test new drug glenzocimab for heart attacks	University of Birmingham
23-Nov-2022	Clinion Achieves GDPR Compliance, continuing its commitment to data privacy and security	Clinion
19-Nov-2022	AJG publishes data from HighTide Therapeutics' Phase 2 study of HTD1801 Treatment in Adults with PSC	HighTide Therapeutics
18-Nov-2022	MODERNA WINS REUTERS PHARMA AWARDS FOR DELIVERING INCLUSIVE TRIALS	Moderna
17-Nov-2022	Evaxion announces promising results from Phase 1/2a clinical trial of personalized DNA cancer immunotherapy EVX-02	Evaxion
15-Nov-2022	Sequana Medical announces positive top-line results from SAHARA Ph. 2a study of DSR 1.0 in diuretic-resistant heart failure patients with persistent congestion and first patient dosed successfully with DSR 2.0 in YUKON	Sequana Medical
15-Nov-2022	Nouscom Announces First Patient Dosed in Phase 2 Randomized Trial with NOUS-209, an ‘off-the shelf’ Neoantigen Cancer Immunotherapy in dMMR/MSI-High Metastatic Colorectal Cancer	Nouscom
15-Nov-2022	Rejuvenate Biomed’s newly appointed Clinical Advisory Board endorses Clinical Phase 2b strategy in sarcopenia	Rejuvenate Biomed
14-Nov-2022	Mural Health Enters the Market to Disrupt Clinical Trial Participant Management Through the Launch of Mural Link Platform	Mural Health
14-Nov-2022	HUTCHMED Announces Positive Topline Result in Fruquintinib Phase III FRUTIGA Study in Second-Line Gastric Cancer in China	HUTCHMED
08-Nov-2022	Bylvay® (odevixibat) Data Presented at AASLD The Liver Meeting® 2022, Demonstrating Native Liver Survival in Children Across PFIC Types	Albireo Pharma